Market capitalization | $37.03b |
Enterprise Value | $49.02b |
P/E (TTM) P/E ratio | 26.76 |
EV/FCF (TTM) EV/FCF | 25.00 |
EV/Sales (TTM) EV/Sales | 3.20 |
P/S ratio (TTM) P/S ratio | 2.42 |
P/B ratio (TTM) P/B ratio | 5.32 |
Revenue growth (TTM) Revenue growth | 3.17% |
Revenue (TTM) Revenue | $15.31b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
25 Analysts have issued a IQVIA forecast:
25 Analysts have issued a IQVIA forecast:
Sep '24 |
+/-
%
|
||
Revenue | 15,314 15,314 |
3%
3%
|
|
Gross Profit | 4,259 4,259 |
6%
6%
|
|
EBITDA | 3,291 3,291 |
7%
7%
|
EBIT (Operating Income) EBIT | 2,164 2,164 |
13%
13%
|
Net Profit | 1,405 1,405 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Provides biopharmaceutical development services and commercial outsourcing services
Head office | United States |
CEO | Ari Bousbib |
Employees | 87,000 |
Founded | 1950 |
Website | www.iqvia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.